# Junta clínica — PT-pseudo_11fe9c6ca833 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_11fe9c6ca833",
  "pid": "PT-pseudo_11fe9c6ca833",
  "task": 1,
  "psa": 190.0,
  "age": 66,
  "months": 2,
  "pirads": "5",
  "psad": 4.097,
  "psav": 41.57,
  "psap": 125.1,
  "vol": 46.38,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.9718793,
  "medhx": "Hypertension, Coronary artery disease",
  "meds": "valsartan, lisinopril, metoprolol, aspirin 80 mg",
  "notes": "PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.",
  "pmhx": [
    "Hypertension",
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "61 kg",
    "height": "167 cm",
    "bmi": "21.9",
    "bp": "125/89 mmHg",
    "hr": "77 bpm",
    "smoking": "Ex-smoker (10 pack-yr, quit 2022)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "02 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer."
    },
    {
      "s": "History",
      "t": "A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses."
    }
  ],
  "occupation": "civil engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "4 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_11fe9c6ca833
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 190.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 4.097 ng/mL²
  - PSA velocity: 41.57 ng/mL/yr
  - Prior PSA: 125.1 ng/mL
  - Prostate volume: 46.38 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9718793 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease
  - Problem list / PMHx: Hypertension, Coronary artery disease
  - Current medication: valsartan, lisinopril, metoprolol, aspirin 80 mg
  - Allergies: NKA
  - Additional notes: PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.

Vitals: weight 61 kg, height 167 cm, BMI 21.9, BP 125/89 mmHg, HR 77 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2022).

Chief complaint: Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer.

History: A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time.

Physical examination: DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses.

Patient info: civil engineer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Tennis 2x/week; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.25
  uncertainty  +/- 0.13 (95% CI 0.00-0.51); among patients it cannot tell apart the outcome was 0.81 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a risk-based pathway based on PI-RADS score, PSA density, and prior biopsy status to guide the decision to perform a biopsy. It states, "In a contemporary series of biopsies, the likelihood of finding a csPCa after follow-up biopsy after a diagnosis of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia (PIN) was only 6-8% - not significantly different from follow-up biopsies after a negative biopsy."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is too simplistic because it fails to account for the patient's high PI-RADS 5 score and the high csPCa probability of 0.97. The guideline suggests that the decision must be guided by a risk-based pathway involving multiple variables, which the classifier ignored.

WHAT WE STILL NEED
the mpMRI prose - the PI-RADS score of 5 mandates a high-risk assessment, which is a decisive factor in the guideline.
the PSA density of 4.097 ng/mL² is a significant variable that, when combined with the PI-RADS score, is used in risk-based pathways to guide the decision.
the prior biopsy status is "Positive" is a decisive factor, as the guideline discusses repeat biopsy after a negative biopsy, which sets the context for re-evaluation.
the PSA velocity of 41.57 ng/mL/yr is a laboratory value that indicates a significant change in the disease course, which is a factor that the guideline makes decisive.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on integrating the high PI-RADS score and PSA density with the prior positive biopsy status to determine the appropriate risk-based pathway.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose regarding lesion size, zone, and extraprostatic extension.
  psa_trend (get_psa_trend) -> Determine the PSA trend to assess the rate of change.
  previous_notes (get_previous_notes) -> Review the management context and prior biopsy findings.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding the lesion size, zone, and extraprostatic extension?
  Q2. How does the PSA velocity of 41.57 ng/mL/yr factor into the risk-based pathway decision?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose regarding lesion size, zone, and extraprostatic extension states: "T2-weighted sequences highlight a sharply demarcated, profoundly hypointense area spanning roughly 28 x 22 x 20 mm within the left peripheral zone at the base and mid-gland. Diffusion-weighted imaging shows intense signal restriction paired with correspondingly low apparent diffusion coefficient readings. Neither extraprostatic extension nor seminal vesicle invasion is evident."
psa_trend
The PSA trend to assess the rate of change shows: {"date": "Dec 2023", "val": 15.3}, {"date": "Apr 2024", "val": 3.3}, {"date": "Sep 2024", "val": 19.1}, {"date": "Feb 2025", "val": 190.0}.
previous_notes
The management context and prior biopsy findings review shows: {"date": "12 Aug 2023", "author": "Dr. E. Mulder (GP)", "text": "Early 2023 screening yielded a PSA of 38 ng/mL, which climbed to 86.0 ng/mL by December 2023. This steep trajectory in a 66-year-old individual necessitated an urgent urology referral to initiate mpMRI planning and comprehensive evaluation."}

WHAT I DID NOT OPEN
laboratory_results was deliberately left closed because the moderator did not ask for it in the plan, and the DRE and headline PSA were already on the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
mpMRI report finding of PI-RADS 5 mandates a high-risk assessment.
PSA trend shows a significant rise, culminating in a PSA of 190.0 ng/mL by Feb 2025.
previous_notes confirm a history of a steep PSA trajectory requiring urgent evaluation.
AGAINST sampling this patient now
Cohort criterion states that the prior positive biopsy means the panel cannot settle the decision.

WHERE THIS LEANS
The combination of a PI-RADS 5 score, a high PSA density of 4.097 ng/mL², and a significant PSA velocity strongly supports a high-risk approach, which aligns with the EAU guideline's emphasis on risk-based pathways.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar successfully answered Q1 by providing the mpMRI prose regarding lesion size, zone, and extraprostatic extension, and answered Q2 by providing the PSA trend data which shows the rate of change. However, the laboratory results remain closed, which was not requested by the moderator's plan.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-EAU's suggestion to proceed with a risk-based pathway, which contradicts the EXPERT-CLASSIFIER's suggestion of "NO BIOPSY" by highlighting the PI-RADS 5 score and PSA velocity as decisive factors.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding the lesion size, zone, and extraprostatic extension? Answered by the registrar via the radiology_report, stating the lesion is in the left peripheral zone with no extraprostatic extension or seminal vesicle invasion.
Q2. How does the PSA velocity of 41.57 ng/mL/yr factor into the risk-based pathway decision? Answered by the registrar via the psa_trend, showing a significant rate of change that supports a high-risk approach.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score (5) because it mandates a high-risk assessment, the PSA density (4.097 ng/mL²) because it is a significant variable in risk-based pathways, and the PSA velocity (41.57 ng/mL/yr) because it indicates a significant change in the disease course. The cohort criterion, which states the prior positive biopsy means the panel cannot settle the decision, is a variable the guideline does not explicitly support as a deciding factor in this context.

MY SUGGESTION TO THE CHAIR
The evidence strongly supports proceeding with a biopsy due to the high PI-RADS score, high PSA density, and significant PSA velocity, which aligns with the EAU's emphasis on risk-based pathways. This should be done firmly.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the prior biopsy status was 'Positive', meaning the diagnosis is already established. This aligns with the EXPERT-CLASSIFIER's suggestion, which was supported by the cohort criterion that the panel cannot settle the decision when a prior diagnosis exists. The prior biopsy status ('Positive') is the factor that prevents further sampling from changing the management pathway.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
